Small Lymphocytic Lymphoma
📧 Sign up to get email alerts when something new happens for Small Lymphocytic Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-07-18Clinical Trial Update: A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL [Phase 1, Phase 2]
A Phase 1/2 study evaluating MS-553 for chronic lymphocytic leukemia and small lymphocytic lymphoma was terminated.
-
CLINICAL_TRIALS trial_result · 2024-07-18Clinical Trial Update: A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma [Phase 1, Phase 2]
MS-553 trial in relapsed/refractory B-cell lymphomas was terminated after Phase 1/2 studies.
-
CLINICAL_TRIALS trial_result · 2024-07-05Clinical Trial Update: Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib [Phase 1]
A Phase 1 clinical trial evaluating the combination of venetoclax with high-dose ibrutinib in chronic lymphocytic leukemia and small lymphoc…
-
CLINICAL_TRIALS research · 2024-06-27Clinical Trial Update: A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy [Phase 2]
This update outlines a Phase 2 clinical trial comparing a fixed-cycle regimen including orelabrutinib with BTK inhibitor monotherapy for chr…
-
CLINICAL_TRIALS trial_result · 2024-06-13Clinical Trial Update: A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies [Phase 1]
Phase Ib study of YY-20394 in participants with B-cell hematologic malignancies has completed, evaluating safety and preliminary activity ac…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2024-06-04FDA Approved: BRUKINSA — Supplemental Application (BeOne Medicines USA, Inc.)
FDA approved a supplemental application for BRUKINSA (zanubrutinib) to update the product labeling.
-
CLINICAL_TRIALS trial_result · 2024-05-29Clinical Trial Update: Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia [Phase 2]
A phase 2 trial evaluating acalabrutinib for relapsed or refractory autoimmune hemolytic anemia in patients with chronic lymphocytic leukemi…
-
CLINICAL_TRIALS trial_result · 2024-05-29Clinical Trial Update: A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. [Phase 3]
A Phase 3 global trial evaluating Lisaftoclax (APG-2575) in combination with acalabrutinib versus immunochemotherapy for newly diagnosed chr…
-
CLINICAL_TRIALS trial_result · 2024-05-09Clinical Trial Update: Biological and Clinical Efficacy of Shingrix in Patients With CLL [NA]
Registry entry describing a trial to assess the biological and clinical efficacy of Shingrix in patients with chronic lymphocytic leukemia a…
-
CLINICAL_TRIALS trial_result · 2024-05-02Clinical Trial Update: Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma [Phase 1]
A Phase 1 study evaluating the safety and preliminary efficacy of the combination of duvelisib and nivolumab in patients with Richter syndro…
-
CLINICAL_TRIALS withdrawal · 2024-04-25Clinical Trial Update: CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL [Phase 1]
A Phase 1 trial investigating CpG-STAT3 siRNA CAS3/SS3 with localized radiation for relapsed/refractory B-cell non-Hodgkin lymphomas has bee…
-
CLINICAL_TRIALS withdrawal · 2024-04-19Clinical Trial Update: Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) [Phase 2, Phase 3]
Clinical trial ULTRA-V (Ublituximab with Umbralisib ± Venetoclax) in CLL/SLL has been terminated, with results posted.
-
CLINICAL_TRIALS trial_result · 2024-04-12Clinical Trial Update: Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
Phase 2 trial investigating curcumin and cholecalciferol in previously untreated stage 0-II chronic lymphocytic leukemia or small lymphocyti…
-
CLINICAL_TRIALS withdrawal · 2024-04-02Clinical Trial Update: A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies [Phase 3]
Phase 3 trial comparing lisocabtagene maraleucel vs investigator's choice in adult relapsed/refractory CLL/SLL has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2024-03-20Clinical Trial Update: Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation [Phase 2]
Phase 2 trial evaluating nivolumab and ibrutinib in relapsed/refractory or high-risk untreated chronic lymphocytic leukemia, small lymphocyt…
-
FDA approval · 2024-02-26FDA Approved: BENDAMUSTINE HYDROCHLORIDE — Supplemental Application (Baxter Healthcare Corporation)
FDA approved a supplemental application for bendamustine hydrochloride (Baxter Healthcare Corporation) under NDA 216078.
-
FDA approval · 2024-02-22FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
The FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.
-
FDA approval · 2024-02-08FDA Approved: VIVIMUSTA — Supplemental Application (Azurity Pharmaceuticals, Inc.)
The FDA approved a supplemental application for VIVIMUSTA (bendamustine hydrochloride) filed by Azurity Pharmaceuticals, Inc., to update/exp…
-
FDA approval · 2024-01-11FDA Approved: BELRAPZO — Supplemental Application (Eagle Pharmaceuticals, Inc)
The FDA approved a supplemental application for Belrapzo (bendamustine hydrochloride) submitted by Eagle Pharmaceuticals, Inc. The action up…
-
CLINICAL_TRIALS trial_result · 2023-11-07Clinical Trial Update: A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL [Phase 3]
Phase 3 trial comparing Zanubrutinib with Bendamustine plus Rituximab in previously untreated chronic lymphocytic leukemia or small lymphocy…
-
CLINICAL_TRIALS trial_result · 2023-10-26Clinical Trial Update: A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib [Phase 2]
Phase 2 trial assessing orelabrutinib in CLL/SLL patients with slow response to ibrutinib is ongoing; current status is unknown.
-
FDA approval · 2023-10-05FDA Approved: LENALIDOMIDE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for lenalidomide submitted by Zydus Pharmaceuticals USA Inc. under ANDA210154, updating the lena…
-
CLINICAL_TRIALS trial_result · 2023-09-21Clinical Trial Update: Allo HSCT Using RIC for Hematological Diseases [Phase 2]
Phase 2 trial evaluating allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for various hematologic dise…
-
CLINICAL_TRIALS trial_result · 2023-08-14Clinical Trial Update: Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 3]
Phase 3 trial comparing ibrutinib plus rituximab versus FCR in untreated chronic lymphocytic leukemia or small lymphocytic lymphoma; status …
-
CLINICAL_TRIALS trial_result · 2023-08-14Clinical Trial Update: Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 3]
This Phase 3 trial compares ibrutinib plus rituximab against fludarabine phosphate, cyclophosphamide, and rituximab in previously untreated …